Havana, May 3. – The clinical trials on a Cuban-made pneumococcal vaccine will begin this year, Finlay Institute Director Concepcion Campa told the press on Thursday. The vaccine is the result of cooperation between the Center for Biomolecular Chemistry and the Finlay Institute, Campa told the National News Agency (AIN) during the 16th International Seminar of the Caribbean Medical Association.
After being tested on people, the heptavalent pneumococcal conjugate vaccine will be available for adults and children to control pneumonia and other illnesses caused by pneumococcus, an exclusively human pathogen.
The scientist highlighted the impact that over ten vaccines prepared by her institution over the past 20 years has had in the national public health system.
They have allowed reducing infant mortality below five deaths per 1,000 live births, Campa said.(Prensa Latina)